About Us
Telix Pharmaceuticals was created to deliver on the promise of nuclear medicine
The field of nuclear medicine has historically lacked clinical momentum and commitment to late-stage product development. Our goal is to rectify this for the benefit of patients.
)
TLX101 for Brain Cancer IPAX-1 Study Update
Melbourne (Australia) – 23 December 2019. Telix Pharmaceuticals has released an update on the progress of its TLX101 product being...
NDA Clinical Briefing Package Submitted to the US FDA
Melbourne (Australia) – 27 Dec 2019. Telix Pharmaceuticals Limited is pleased to announce that it has submitted a complete clinical...
Webcast of CEO’s presentation to Jefferies 2019 London Healthcare Conference
Melbourne (Australia) – 25th November 2019. Telix Pharmaceuticals Limited has today announced that Group CEO, Dr Christian Behrenbruch, presented at...
Telix Pharmaceuticals and ATONCO Partner for Bladder Cancer
Melbourne (Australia) and Nantes (France) – 16, Dec 2019. Telix Pharmaceuticals Limited and French company ATONCO S.A.S today announce that...